Sellas, Life

Sellas Life Sciences: A 41% Survival Benefit and a $172.5 Million Equity Raise Move in Tandem

Published on 11/21/2026 at 16:21 | Editorial boerse-global.de
Sellas priced a $172.5M offering at $13.00, below the prior close, days after galinpepimut-S met the Phase 3 REGAL overall survival endpoint in AML.
Sellas Life Sciences Illustration mit AI erstellt.

Sellas Life Sciences packed two very different pieces of news into a single week. The clinical side brought a clear win; the financing side brought fresh capital — and a lower share price. The stock fell 8.1% on Friday after the company priced a public offering below the previous close, with shares sold at $13.00 apiece.

REGAL Hits Its Primary Endpoint

The medical headline came on November 17, when Sellas reported that galinpepimut-S met the primary endpoint of overall survival in the Phase 3 REGAL trial in acute myeloid leukemia. Median overall survival reached 24.0 months on the treatment arm, compared with 14.7 months for the best available therapy. According to the company, the risk of death fell by 41%. Sellas put the hazard ratio at 0.59 and the p-value at 0.035.

Those figures describe different facets of the same result. The hazard ratio and the comparison of median survival times should not be conflated — one captures the relative reduction in mortality risk, the other the absolute difference in months. Sellas now plans to meet with the FDA and is pushing ahead with preparations for a marketing application.

Should investors sell immediately? Or is it worth buying Sellas Life Sciences?

The Placement, Priced and Closed

Alongside the data, Sellas went to the market with a public share offering, closing the placement including the fully exercised greenshoe option. The company sold 13,269,231 shares at $13.00 each, generating gross proceeds of $172.5 million before costs. The banks involved exercised their option to buy additional shares in full.

The distinction between gross proceeds and the net cash actually available after fees matters here, as does the nature of the greenshoe: its full exercise belongs to the financing, not to any assessment of galinpepimut-S's efficacy. As of September 30, Sellas had reported cash and cash equivalents of $134.7 million.

A Second Program Running in Parallel

Beyond REGAL, a Phase 2 study of SLS009 in first-line acute myeloid leukemia is under way. Sellas said on November 12 that 40 patients had been enrolled, with preliminary initial results expected in the fourth quarter of 2026.

For investors, the week offers two separate yardsticks for the same stock. A met study goal and a dilutive financing can shape valuation at the same time. New shares do not diminish the clinical achievement — but strong trial data do not erase the terms on which the equity was issued, either.

Ad

Sellas Life Sciences Stock: New Analysis - 21 November

Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Sellas Life Sciences analysis...

Disclaimer...
en | US81642T2096 | SELLAS | boerse | 70542887 |